Cleavage Susceptibility of Reovirus Attachment Protein σ1 during Proteolytic Disassembly of Virions Is Determined by a Sequence Polymorphism in the σ1 Neck

JAMES D. CHAPPELL,1,2 ERIK S. BARTON,2,3 TRENT H. SMITH,1 GEOFFREY S. BAER,2,3 DAVID T. DUONG,1 MAX L. NIBERT,1,4 AND TERENCE S. DERMODY1,2,3,*

Departments of Pediatrics1 and Microbiology and Immunology3 and Elizabeth B. Lamb Center for Pediatric Research,2 Vanderbilt University School of Medicine, Nashville, Tennessee 37232, and Institute for Molecular Virology, University of Wisconsin, Madison, Wisconsin 537064

Received 6 March 1998/Accepted 18 June 1998

A requisite step in reovirus infection of the murine intestine is proteolysis of outer-capsid proteins to yield infectious subvirus particles (ISVs). When converted to ISVs by intestinal proteases, virions of reovirus strain type 3 Dearing (T3D) lose 90% of their original infectivity due to cleavage of viral attachment protein σ1. In an analysis of eight field isolate strains of type 3 reovirus, we identified one additional strain, type 3 clone 31 (T3C31), that loses infectivity and undergoes σ1 cleavage upon conversion of virions to ISVs. We examined the σ1 deduced amino acid sequences of T3D and the eight field isolate strains for a correlation between sequence variability and σ1 cleavage. The σ1 proteins of T3D and T3C31 contain a threonine at amino acid position 249, whereas an isoleucine occurs at this position in the σ1 proteins of the remaining strains. Thr249 occupies the d position of a heptad repeat motif predicted to stabilize σ1 oligomers through a-helical coiled-coil interactions. This region of sequence comprises a portion of the fibrous tail domain of σ1 known as the neck. Substitution of Thr249 with isoleucine or leucine resulted in resistance to cleavage by trypsin, whereas replacement with asparagine did not affect cleavage susceptibility. These results demonstrate that amino acid position 249 is an independent determinant of T3D σ1 cleavage susceptibility and that an intact heptad repeat is required to confer cleavage resistance. We performed amino-terminal sequence analysis on the σ1 cleavage product released during trypsin treatment of T3D virions to generate ISVs and found that trypsin cleaves σ1 after Arg245. Thus, the sequence polymorphism at position 249 controls cleavage at a nearby site in the neck region. The relevance of these results to reovirus infection in vivo was assessed by treating virions with the contents of a murine intestinal wash under conditions that result in generation of ISVs. The pattern of σ1 cleavage susceptibility generated by using purified protease was reproduced in assays using the intestinal wash. These results provide a mechanistic explanation for σ1 cleavage during exposure of virions to intestinal proteases and may account for certain strain-dependent patterns of reovirus pathogenesis.

Following oral inoculation into newborn mice, mammalian reoviruses undergo primary replication in intestinal tissue and spread to the central nervous system (64). However, not all reovirus strains are capable of productive infection in intestinal tissue. Prototype type 3 reovirus strain Dearing (T3D) grows poorly in the murine intestine after oral inoculation. In contrast, prototype type 1 reovirus strain Lang (T1L) grows well in intestinal tissue and is capable of systemic spread (9, 32, 35, 54). Proteolytic processing of reovirus virions in the intestinal lumen (6, 10) or in the endocytic compartment (3, 11, 15, 56, 59) results in generation of infectious subvirus particles (ISVs) (48) and is required for reovirus to establish productive infection of either animal hosts (1, 6) or cultured cells (3, 19, 59). Under conditions that result in generation of ISVs, treatment of T3D virions in vitro with either chymotrypsin or trypsin is associated with cleavage of viral attachment protein σ1 and a 10-fold decrease in viral infectivity (46). Identical treatment of T1L is not associated with σ1 cleavage or reduced infectivity. Strain-dependent differences in ISVP infectivity loss and σ1 cleavage cosegregate in genetic analyses with the σ1-encoding S1 gene, which indicates that cleavage susceptibility of T3D σ1 protein is an intrinsic property of this molecule and that infectivity loss experienced by T3D ISVPs is causally linked to σ1 cleavage (46). Furthermore, studies of T1L × T3D reassortant viruses show that the S1 gene is the primary determinant of strain-specific differences in growth of reovirus in the murine intestine (9). These findings suggest that the infectivity loss experienced by T3D following oral inoculation results from susceptibility of its σ1 protein to cleavage by intestinal proteases.

The σ1 protein is a fibrous protein with a head-and-tail morphology (4, 14, 24, 25). In virions, σ1 exists as an oligomer (7, 39, 58) located at the vertices of the virion icosahedron (20, 25). Results from genetic and biochemical studies of σ1 protein suggest the presence of two discrete receptor-binding domains in σ1 of type 3 reovirus. A domain in the tail is important for binding sialic acid (16, 17, 46, 55), and a domain in the head is important for binding an unidentified receptor on L cells (21, 45, 60, 67, 70) and determining viral tropism within the murine central nervous system (8, 33). Binding of sialic acid by σ1 is the basis for hemagglutination (HA) by type 3 reovirus (2, 17, 26, 27, 49, 50) and growth of type 3 reovirus in murine erythroleukemia cells (16, 55).

Following treatment of T3D virions with chymotrypsin to generate ISVPs, monoclonal antibody (MAb) G5, which binds the T3D σ1 head (8), is markedly diminished in its capacity to bind viral particles and neutralize infectivity (46). This result...
suggests that the σ1 head is released from the viral particle following protease treatment of T3D virions. However, T3D ISVPs retain the ability to bind cell surface sialic acid (46), which suggests that the σ1 tail domain remains associated with ISVPs. Studies using protease treatment of σ1 purified from virions (70) and expressed σ1 protein (22) indicate that cleavage is localized to a highly protease-sensitive region near the middle of σ1 primary sequence. Based on predictions of σ1 secondary structure (47) and image reconstructions of σ1 protein visualization by electron microscopy (24), protease-sensitive sequences are proposed to represent a head-proximal flexible portion of the tail termed the neck. These results have been reconciled in a model of T3D ISVP formation in which σ1 is cleaved within the neck region between receptor-binding domains on the head and tail (46). However, the site of σ1 cleavage on T3D ISVPs has not been identified, and the mechanism of cleavage sensitivity is unknown.

In this study, we performed experiments to determine the mechanism of σ1 susceptibility to cleavage by intestinal proteases during generation of ISVPs. Our results suggest that σ1 cleavage sensitivity is influenced by subunit interactions in the σ1 oligomer. Furthermore, results from these studies strongly support the existence of discontinuous receptor-binding domains in the σ1 head and tail (16, 46).

MATERIALS AND METHODS

Cells and viruses. Spinner culture-adapted L cells were grown in either suspension or monolayer cultures, using Joklik’s modified Eagle’s minimal essential medium (Irvine Scientific, Santa Ana, Calif.) supplemented to contain 5% fetal bovine serum (Summit Biotechnology, Fort Collins, Colo.), 2 mM L-glutamine, and 100 U of penicillin, 100 μg of streptomycin, and 0.25 μg of amphotericin per ml (Irvine). Spodoptera frugiperda (SF21) insect cells were grown in either suspension or monolayer cultures, using Grace’s medium (Gibco, Grand Island, N.Y.) supplemented to contain 10% fetal bovine serum plus 100 U of penicillin, 100 μg of streptomycin, and 0.25 μg of amphotericin per ml. Reovirus strain T3D is a laboratory stock. Isolate field strains type 3 clone 9 (T3C9), type 3 clone 18 (T3C18), type 3 clone 31 (T3C31), type 3 clone 43 (T3C43), type 3 clone 44 (T3C44), type 3 clone 84 (T3C84), and type 3 clone 93 (T3C93) were obtained originally from the collection of Leon Rosen (18, 53–55). Purified virion preparations were made from second- and third-passage L-cell lystate stocks of twelve-plaque-purified virus as previously described (25). To obtain a virion preparation containing 2,5-labeling forms, Easy Tag Express-[pH 6.8], 4% 2-mercaptoethanol, 2% SDS, 0.02% bromophenol blue) and incubated on a rotator at 0°C. After incubation, culture medium was replaced with methionine-free Grace’s medium (Gibco) supplemented to contain 10% fetal bovine serum, 100 U of penicillin, 100 μg of streptomycin, and 0.25 μg of amphotericin per ml. Reovirus ISVPs retain the ability to bind cell surface sialic acid (46), following protease treatment of T3D virions. However, T3D ISVPs are also sensitive to protease cleavage near the middle of ISVPs, retaining the ability to bind cell surface sialic acid (46).

Cloning and mutagenesis of σ1 gene cDNAs. The σ1-encoding S1 gene cDNAs of strains T3D, T3C9, and T3C84 were generated by using reverse transcription–PCR (36) and cloned into the pcR2.1 vector (Invitrogen, San Diego, Calif.). S1 genes were amplified with primers specific for the noncoding regions of the T3D S1 gene. Site-directed mutants of the T3D S1 gene were produced by using the splice-overlap-extension PCR technique (30). Primers bearing desired mutations in the S1 gene were used in independent primary reactions to generate S1 gene fragments having sequence complementarity over the terminal 20 nucleotides. The complementary primer sets used for mutagenesis were as follows (nucleotides differing from wild-type T3D S1 sequence are underlined): 5′-AGGCCGAAAT TGAGCAGAATGCTAAATGGC-3′ (Thr249→Ile), 5′-AGGCGGAAAT TGAGCAGAATGCTAAATGGC-3′ (Thr249→Leu), and 5′-AGGCCGAAATTGAGCAGAATGCTAAATGGC-3′ (Thr249→Asn). Reaction mixtures included 0.5 μg of recombinant pcR2.1 plasmid template, 0.2 μg of S1-specific primers, 200 μM each deoxynucleoside triphosphate, and 2.5 μl of Pfu DNA polymerase (Stratagene, La Jolla, Calif.) in a total volume of 50 μl of Pfu reaction buffer (Stratagene). Reactions were subjected to 40 cycles of a thermal cycle consisting of 94°C for 1 min, 55°C for 2 min, and 72°C for 3 min. The final cycle was followed by incubation at 72°C for 20 min. Primary PCR products were resolved in a 1% Tris-borate-EDTA agarose gel containing ethidium bromide, and the desired amplification product was allowed to migrate onto DE-81 chromatography paper (Whatman, Maidstone, England) inserted into the gel, followed by elution in a solution of 1 M LiCl, 10 mM Tris (pH 7.6), and 1 mM EDTA in 10% ethanol. Eluted DNA was concentrated by ethanol precipitation and reconstituted in water.

Secondary PCR products were amplified in reaction mixtures containing 1 pmol each of the two purified primary PCR products, 0.2 μg of S1-specific primers, complementary to T3D S1 gene segment termini, 200 μM each deoxynucleoside triphosphate, and 5 μl of Taq DNA polymerase (Promega, Madison, Wis.) in a total volume of 50 μl of PCR Optimizer buffer (Invitrogen) adjusted to pH 9.0 and 2 mM MgCl2. Thermal cycling parameters were identical to those listed for the primary reactions. Products from the secondary PCR were gel purified and cloned into the pcR2.1 vector. Sequence fidelity was confirmed for σ1-encoding regions of all S1 gene cDNAs in recombinant pcR2.1 constructs; nucleotide sequences were determined by automated analysis using an ABI model 377 (PE- Applied Biosystems, Norwalk, Conn.) or an automated sequencer (Pharmacia, Tokyo, Japan) using [35S]ATP. Error-free S1 gene cDNAs were then cloned into baculovirus transfer vectors.

Expression and purification of recombinant σ1 proteins. First- or second-passage recombinant baculovirus stocks were used to infect SF21 cell monolayers (106 cells) at a multiplicity of infection of ≤1 PFU per cell. After 20 h of incubation, culture medium was replaced with methionine-free Grace’s medium (Gibco) supplemented to contain 10% fetal bovine serum, 100 U of penicillin, 100 μg of streptomycin, and 0.25 μg of amphotericin per ml. Reovirus σ1 gene cDNAs were generated by cloning into pBacPAK5 and pBacPAK9 baculovirus transfer vectors (Clontech), followed by lipofection-mediated cotransfection of plasmid recombinants and linearized BacPAK5 AcMNPV DNA (Clontech) into SF21 cells according to the supplier’s instructions. After 5 days of incubation, recombinant virus clones were isolated by plaque purification on monolayers of SF21 cells and amplified by two passages in SF21 cells.

Destruction of reovirus virions with intestinal proteases. Purified reovirus virions at a concentration of 2 × 1010 particles per ml in virion storage buffer (150 mM NaCl, 10 mM MgCl2, 10 mM Tris [pH 7.5]) were digested at 37°C with 200 μg of Nα-p-tosyl-l-lysine chloromethyl ketone (TLCK)-treated bovine a-chymotrypsin (Sigma Chemical Co., St. Louis, Mo.) per ml for various intervals. Digestion reactions were stopped by adding 5 mM phenylmethylsulfonyl fluoride (Sigma) to the treatment mixtures and cooling at 0°C.

Determination of virus titer after protease treatment of reovirus virions. Virus titers after protease treatment of virions was determined by plaque assay as previously described (62).

SDS-PAGE of reovirus structural proteins. Discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed as previously described (37). In preparation for electrophoresis, 7%–12% gradient gels were prepared in 29.5% acrylamide and 0.8% bisacrylamide, and then run horizontally at 150 V constant current until the dye front reached the bottom of the gel. Gels were dried onto filter paper (Bio-Rad Laboratories, Hercules, Calif.) and vacuum and exposed to Biomax MR film (Eastman Kodak Co., Rochester, N.Y.). HA assay. HA assays using virions and ISVPs were performed as previously described (46).

on August 14, 2017 by guest
http://jvi.asm.org/ Downloaded from
Proteins were electrophoresed onto a polyvinylidene difluoride membrane by using a Mini Transblot apparatus (Bio-Rad) operated at 30-V constant voltage overnight. Protein bands were visualized by Coomassie blue staining, and a band migrating at approximately 25 kDa was excised and subjected to sequence analysis by Edman degradation using a Procise 492 protein sequencer (PE-Applied Biosystems, Foster City, Calif.).

The procedure for isolating a σ1 cleavage product also was performed with purified 35S-labeled T3D virions. In this case, ISVPs contained in trypsin digests of virions were not removed prior to addition of MAb G5. Polypeptides recovered with MAb G5 were subjected to electrophoresis under reducing conditions in an SDS–14% polyacrylamide gel and subjected to autoradiography. The Coomassie blue-stained σ1 cleavage product on the polyvinylidene difluoride membrane was verified by comparison with the autoradiogram.

Assessment of σ1 cleavage upon treatment with virions with a murine intestinal wash. Three-day-old NIH Swiss mice (Harlan Sprague Dawley) were euthanized, and the entire small and large intestine was resected. Contents of 20 intestines were harvested in a total volume of 5 ml of virion storage buffer by repeated flushing using a 1-ml syringe and 25-gauge needle. Material was centrifuged at 23,000 × g for 30 min, and clarified supernatants were used in reactions containing $2 \times 10^{12}$ particles per ml that were treated with chymotrypsin at 37°C for 180 min. Infectious titers of virion preparations before and after treatment were determined by plaque assay using L-cell monolayers (Fig. 1). Protein bands were visualized by Coomassie blue staining, and a band at approximately 25 kDa was excised and subjected to sequence analysis by Edman degradation using a Procise 492 protein sequencer (PE-Applied Biosystems, Foster City, Calif.).

RESULTS

Type 3 reovirus field isolate strains vary in infectivity and σ1 cleavage during treatment with intestinal proteases to generate ISVPs. Treatment of virions of reovirus strain T3D with either chymotrypsin or trypsin under conditions to generate ISVPs results in approximately a 10-fold loss in infectivity and cleavage of σ1 protein (46). To determine whether other type 3 reovirus strains also lose infectivity when converted to ISVPs, purified virions of eight type 3 field isolate strains were treated with chymotrypsin under conditions to generate ISVPs, and aliquots of the treatment mixtures were titrated on L-cell monolayers (Fig. 1). Strain T3C31 was the only strain other than T3D to exhibit a decrease in infectivity. Similar to ISVPs of T3D, which lost about 90% of pretreatment infectivity, ISVPs of T3C31 lost approximately 84% of the original infectivity of virions. Changes in T3C31 infectivity recapitulated the kinetic profile observed when chymotrypsin was used to generate ISVPs of T3D (46); a slight increase in viral titer occurred at early time points of protease treatment, followed by a rapid decline in titer that approached its lowest point by 60 min of treatment (Fig. 2). Infectivity of the remaining field isolate strains was slightly (as much as twofold in the cases of T3C18 and T3C43) increased after treatment with chymotrypsin to generate ISVPs. Consistent with the effect of chymotrypsin on viral infectivity, strains T3D and T3C31 lost ≥90% of the original infectivity following treatment with trypsin (data not shown). Thus, infectivity loss associated with T3D ISVPs also is common to T3C31 ISVPs but is not a universal property of type 3 reoviruses.

To determine whether differences in viral infectivity of type 3 reovirus strains correlate with differences in susceptibility of their σ1 proteins to proteolytic cleavage, viral proteins in chymotrypsin treatment mixtures were analyzed by SDS-PAGE (Fig. 3). Findings consistent with generation of ISVPs, loss of outer-capsid protein σ3, and appearance of the stable cleavage product, δ, of outer-capsid protein μ1C were observed in these experiments. Following treatment with chymotrypsin, bands corresponding to σ1 cleavage product CHT were observed in T3D and T3C31 ISVPs, as well as in T3C9, T3C18, T3C31, T3C43, T3C44, T3C45, T3C84, and T3C93. The stability of the band corresponding to σ1 cleavage product CHT was verified by comparison with the autoradiogram.

VOL. 72, 1998 PROTEOLYTIC CLEAVAGE OF TYPE 3 REOVIRUS σ1 PROTEIN 8207

FIG. 1. Changes in viral infectivity during generation of ISVPs by using chymotrypsin. Purified virions of T3D, T3C9, T3C18, T3C31, T3C43, T3C44, T3C45, T3C84, and T3C93 at a concentration of $2 \times 10^{12}$ particles per ml were treated with chymotrypsin at 37°C for 180 min. Infectious titers of virion preparations before and after treatment were determined by plaque assay using L-cell monolayers (Fig. 1). Strain T3C31 was the only strain other than T3D to exhibit a decrease in infectivity. Similar to ISVPs of T3D, which lost about 90% of pretreatment infectivity, ISVPs of T3C31 lost approximately 84% of the original infectivity of virions. Changes in T3C31 infectivity recapitulated the kinetic profile observed when chymotrypsin was used to generate ISVPs of T3D (46); a slight increase in viral titer occurred at early time points of protease treatment, followed by a rapid decline in titer that approached its lowest point by 60 min of treatment (Fig. 2). Infectivity of the remaining field isolate strains was slightly (as much as twofold in the cases of T3C18 and T3C43) increased after treatment with chymotrypsin to generate ISVPs. Consistent with the effect of chymotrypsin on viral infectivity, strains T3D and T3C31 lost ≥90% of the original infectivity following treatment with trypsin (data not shown). Thus, infectivity loss associated with T3D ISVPs also is common to T3C31 ISVPs but is not a universal property of type 3 reoviruses.

To determine whether differences in viral infectivity of type 3 reovirus strains correlate with differences in susceptibility of their σ1 proteins to proteolytic cleavage, viral proteins in chymotrypsin treatment mixtures were analyzed by SDS-PAGE (Fig. 3). Findings consistent with generation of ISVPs, loss of outer-capsid protein σ3, and appearance of the stable cleavage product, δ, of outer-capsid protein μ1C were observed in these experiments. Following treatment with chymotrypsin, bands corresponding to σ1 cleavage product CHT were observed in T3D and T3C31 ISVPs, as well as in T3C9, T3C18, T3C31, T3C43, T3C44, T3C45, T3C84, and T3C93. The stability of the band corresponding to σ1 cleavage product CHT was verified by comparison with the autoradiogram.

FIG. 2. Time course of change in T3C31 infectivity during generation of ISVPs by using chymotrypsin. Purified virions of strain T3C31 at a concentration of $2 \times 10^{12}$ particles per ml were treated with chymotrypsin at 37°C. At the times indicated, reactions were terminated, and infectious titers of virion preparations were determined by plaque assay using L-cell monolayers. Changes in viral infectivity are expressed as the ratio of log_{10} viral titer relative to 0 min of chymotrypsin treatment. Shown are the means and standard deviations of three independent experiments.

FIG. 3. Electrophoretic analysis of viral structural proteins of type 3 reovirus strains following treatment with chymotrypsin to generate ISVPs. Purified 35S-labeled virions of T3D, T3C9, T3C18, T3C31, T3C43, T3C44, T3C45, T3C84, and T3C93 at a concentration of $2 \times 10^{12}$ particles per ml were treated with chymotrypsin (CHT) at 37°C for 60 min. Equal numbers of treated and untreated viral particles ($2 \times 10^{11}$) were dissociated in sample buffer and loaded into wells of an SDS–10% polyacrylamide gel. After electrophoresis, gels were prepared for fluorography and exposed to film. Viral proteins are labeled.
corresponding to σ1 proteins of T3D and T3C31 were lost, whereas bands corresponding to σ1 proteins of the remaining seven strains were not. Thus, changes in viral infectivity after chymotrypsin treatment correlate with the status of σ1 protein observed by SDS-PAGE: strains that exhibited decreased infectivity have cleaved σ1 proteins. These findings are in agreement with previous studies of virions and ISVPs of T1L and T3D (46) and demonstrate a consistent correlation between changes in viral infectivity and σ1 cleavage susceptibility during generation of ISVPs.

**Protease treatment of type 3 field isolate strains increases their capacity to produce HA.** T3D ISVPs demonstrate an increase in HA titer relative to T3D virions (46, 63), which suggests that the HA domain in σ1 protein is altered by a conformational change in σ1 or further exposed by proteolysis of σ3 and μ1/μ1C proteins during generation of ISVPs. However, it is also possible that cleavage of T3D σ1 protein facilitates the enhanced capacity of T3D ISVPs to produce HA. To determine whether chymotrypsin-mediated cleavage of σ1 protein plays a role in increased HA titer, we treated purified virions of the five HA-positive field isolate strains (T3C9, T3C18, T3C31, T3C45, and T3C93) with chymotrypsin to generate ISVPs and then tested the treatment mixtures for their capacity to agglutinate human type O erythrocytes (Fig. 4). Commensurate with an increase in T3D HA titer of approximately 10-fold, the HA titer of the type 3 field isolate strains increased 4- to 16-fold following chymotrypsin treatment. Therefore, in contrast to changes in viral infectivity, the increased capacity of type 3 ISVPs to produce HA relative to virions is independent of σ1 cleavage status. These data suggest that a domain of σ1 protein important for HA is altered with respect to conformation or environment during conversion of virions to ISVPs.

**Comparison of the deduced amino acid sequences of σ1 proteins link infectivity loss and σ1 cleavage to amino acid 249.** The correlation of sequence variability with biologic polymorphisms has provided important information about structure-function relationships in reovirus σ1 protein (16, 17, 68). We previously determined the deduced σ1 amino acid sequences of the eight field isolate strains used in this study and found a high degree of conservation among these strains and T3D (85 to 99% sequence identity in pairwise sequence comparisons [18]). Therefore, to identify sequences in σ1 associated with infectivity loss and σ1 cleavage, we examined the σ1 amino acid sequences of T3D and the field isolate strains for residues unique to T3D among these strains exhibits chymotrypsin-mediated infectivity loss and σ1 cleavage, we examined the six σ1 sequences of the six strains, T3D, T3C43, T3C44, T3C45, T3C84, and T3C93, are very similar, showing variation at only 19 of 455 total amino acid positions of a heptad repeat motif characteristic of N-terminal coiled coils (42). The mean (± standard deviation) ratio of log2 HA titer at 180 and 0 min of chymotrypsin treatment is shown for each strain.

**Analysis of cleavage susceptibility of expressed σ1 proteins altered at amino acid position 249.** The importance of amino acid residue 249 in cleavage of σ1 by intestinal proteases was assessed using baculovirus-expressed, purified T3D σ1 proteins modified by site-directed mutagenesis. Consistent with the chymotrypsinmediated cleavage status of the T3C43, T3C44, T3C45, and T3C93 (Fig. 5). Thus, Thr[Superscript 249] is unique to T3D and T3C31, which suggests that the amino acid residue at position 249 determines susceptibility of σ1 protein to proteolytic cleavage.

![Figure 4](http://jvi.asm.org/)

**FIG. 4.** Changes in viral HA capacity during generation of ISVPs by using chymotrypsin. Purified virions of T3D, T3C9, T3C18, T3C31, T3C45, and T3C93 at a concentration of 2 × 10¹⁰ particles per ml were treated with chymotrypsin at 37°C for 180 min. HA activity of virion preparations was determined by endpoint titration using human type O erythrocytes and serial dilutions of virus. Changes in HA activity are expressed as the ratio of log₂ HA titer at 180 and 0 min of chymotrypsin treatment. Shown are the means and standard deviations of three independent experiments.

![Figure 5](http://jvi.asm.org/)

**FIG. 5.** Identification of residues important for infectivity loss and σ1 cleavage of reovirus strains T3D and T3C31. (A) Model of σ1 secondary structure (47) and morphologic domains of σ1 (T(i), T(ii), T(iii), T(iv), and H) described previously (24) are shown and scaled proportionally to the domains identified in electron microscopic images of σ1 isolated from virions (24). Amino acid positions are scaled according to their predicted relationships to individual σ1 morphologic domains (47). (B) Alignment of σ1 amino acid sequences. DEDuced σ1 amino acid sequence of strains T3D and T3C31 were aligned with those of T3C9, T3C18, T3C43, T3C44, T3C45, T3C84, and T3C93 (18) and examined for correlation of sequence variability with viral infectivity changes and σ1 cleavage susceptibility during the generation of ISVPs by using chymotrypsin. The σ1 proteins of T3D and T3C31 contain a threonine residue at position 249, whereas all other σ1 proteins contain an isoleucine at that position. Shown is an alignment of amino acid residues 239 through 252, which are proposed to form α-helical coiled coil comprising a portion of the σ1 neck (47). In the alignment of σ1 sequences, residues in boxes are found in the α or d position of a heptad repeat motif characteristic of α-helical coiled coils (42).
motrypsin sensitivity of virion-associated T3D σ1 protein (Fig. 3), expressed wild-type T3D σ1 protein was cleaved by chymotrypsin, resulting in the accumulation of cleavage products of \( \pm 30 \) kDa as assessed by SDS-PAGE (Fig. 6A). Mutant σ1 proteins in which Thr\(^{249}\) was replaced with isoleucine, leucine, or asparagine were also cleaved by chymotrypsin. To determine whether chymotrypsin sensitivity is a feature of type 3 σ1 proteins expressed and tested under conditions used in this study, expressed σ1 proteins of strains T3C9 and T3C84 were tested in protease assays using chymotrypsin and trypsin (Fig. 7). Neither T3C9 nor T3C84 virions lose infectivity upon conversion to ISVPs by using chymotrypsin (Fig. 1), and their σ1 proteins are resistant to cleavage (Fig. 3). However, expressed T3C9 and T3C84 σ1 proteins were cleaved following treatment with chymotrypsin. These results indicate that cleavage of the Thr\(^{249}\)→Ile and Thr\(^{249}\)→Leu mutant T3D σ1 proteins by chymotrypsin is an inherent property of expressed σ1 protein and that the role of amino acid position 249 in cleavage of σ1 by chymotrypsin cannot be addressed using this experimental system.

ISVPs of T3D generated by using trypsin exhibit the properties of viral infectivity loss and σ1 cleavage characteristic of ISVPs generated by using chymotrypsin (46). Therefore, we tested the effect of trypsin on expressed σ1 proteins, examining first the control proteins, T3C9 σ1 and T3C84 σ1 (Fig. 7). These σ1 proteins exhibited resistance to cleavage by trypsin, which indicated that this enzyme would be suitable to test the role of position 249 in σ1 protease susceptibility. Wild-type T3D σ1 protein was cleaved by trypsin into two major fragments in the range of \( 25 \) kDa (Fig. 6B). These stable cleavage products most likely represent the amino-terminal 25/26-kDa and carboxy-terminal 23/24-kDa fragments observed previously following trypsin treatment of T3D σ1 proteins purified from virions (70) or expressed by recombinant baculovirus (22). Upon replacement of Thr\(^{249}\) with Ile, which is found at position 249 in the seven chymotrypsin-resistant σ1 proteins, T3D σ1 was resistant to cleavage by trypsin, showing very little loss in band intensity at the highest concentration of enzyme used (18 \( \mu \)g per ml). In contrast, only a small fraction of intact wild-type σ1 remained at the lowest enzyme concentration (2 \( \mu \)g per ml), and a full-length σ1 band was barely detectable at higher concentrations. Thus, an isoleucine at amino acid position 249 confers resistance to σ1 cleavage by the intestinal protease, trypsin.

We next ascertained whether there exists an absolute requirement for isoleucine to confer protease resistance. Thr\(^{249}\) was substituted with the isoleucine isomer, leucine. Like the Thr\(^{249}\)→Ile mutant σ1 protein, the Thr\(^{249}\)→Leu mutant was resistant to cleavage by trypsin and underwent only moderate proteolysis at the highest concentration of enzyme used (Fig. 6B). These results suggest that the critical determinant of protease resistance is the presence of an apolar residue at position 249. To test this hypothesis, we used an additional σ1 mutant substituted at position 249 with the polar amino acid, asparagine. When treated with trypsin, the Thr\(^{249}\)→Asn mutant exhibited a cleavage profile virtually indistinguishable from that of wild-type σ1 (Fig. 6B). Thus, our findings suggest that susceptibility of T3D σ1 to proteolytic cleavage depends on the type of amino acid at position 249, where apolar and polar residues respectively confer cleavage resistance and sensitivity.

Identification of a cleavage site in the σ1 protein of T3D ISVPs generated by protease treatment of virions. The site at which trypsin cleaves T3D σ1 during the generation of ISVPs was determined by amino-terminal sequence analysis of the σ1 cleavage product liberated by protease treatment of purified virions. Virions were treated with trypsin, and the carboxy-terminal fragment of σ1 was captured by using MAb G5, which binds the virion-distal head domain (8) (Fig. 8A). Trypsin treatment of T3D virions resulted in the loss of σ3 protein and
appearance of the μL cleavage product, δ, consistent with the formation of ISVPs. A single σ1 cleavage product of approximately 25 kDa was purified from the digestion reaction using MAb G5 and subjected to eight cycles of Edman microsequencing. This analysis revealed the unambiguous amino acid sequence Ile-Gly-Ala-Thr-Glu-Gln-Ser-Tyr, which corresponds exactly to T3D σ1 amino acid residues 246 to 253 (Fig. 8B). An arginine residue occupies amino acid position 245 of T3D σ1, and cleavage at this site is congruous with the action of trypsin at the carboxy-terminal side of basic residues (12). The sequence contained in residues 246 to 253 is not repeated elsewhere in T3D σ1. Therefore, results from amino-terminal sequence analysis indicate that virion-associated σ1 protein is cleaved by trypsin between Arg245 and Ile246, which are proposed to form a portion of the σ1 neck (47).

Use of a murine intestinal wash to test the stability of type 3 σ1 protein during proteolytic conversion of virions to ISVPs. To determine whether a natural milieu of intestinal enzymes would reproduce the pattern of σ1 cleavage susceptibility observed after treatment of type 3 reovirus virions with purified chymotrypsin, virions were treated with the contents of an intestinal lavage from newborn mice. As a control for resistance of σ1 protein to proteolytic cleavage, we first treated virions of strain T1L with the intestinal wash (Fig. 9). The σ1 protein of this strain was shown previously to remain intact when ISVPs are generated in vitro by using chymotrypsin or trypsin (46) and when ISVPs are generated in the intestinal lumen of newborn mice (10). SDS-PAGE analysis of viral proteins showed that purified virions of T1L were converted to ISVPs upon treatment with the intestinal wash. The σ1 protein of these particles appeared fully intact, which indicates that ISVPs generated by this method are suitable for study of σ1 susceptibility to proteolysis. Purified virions of T3D, T3C9, T3C31, and T3C84 also were converted to ISVPs upon treatment with the intestinal wash (Fig. 9). Bands corresponding to full-length T3C9 and T3C84 σ1 proteins were not significantly different from those of untreated virions, even at the highest concentration of intestinal wash (≈83% [vol/vol]). However, the σ1 proteins of T3D and T3C31 were very susceptible to cleavage under these conditions; σ1 protein bands of these strains were not detectable at the lowest concentration of intestinal wash tested (≈4% [vol/vol]). Other than loss of σ1 protein, there were no remarkable differences between the ISVP protein profiles of the σ1-unstable and σ1-stable type 3 strains. The same cleavage profiles were observed when ISVPs were recovered in intestinal washes following intragastric inoculation of newborn mice with 35S-labeled virions (data not shown). These results mirror those obtained in assays using purified intestinal enzymes and strongly suggest that strain-specific differences in σ1 stability observed in assays using in vitro-generated ISVPs are also exhibited in the intestinal lumen.

**DISCUSSION**

We report here the identification of an amino acid residue in the neck region of T3D σ1 protein, Thr249, that determines susceptibility of σ1 to proteolytic cleavage during ISVP forma-

---

FIG. 8. Amino-terminal sequence analysis of σ1 cleavage products liberated during the generation of T3D ISVPs by using trypsin. (A) Isolation of a σ1 cleavage product by using anti-σ1 MAb G5. Purified 35S-labeled virions of T3D at a concentration of 2 × 10^13 particles per ml were treated with 100 μg of trypsin per ml at 15°C for 30 min. Cleavage products were purified by using MAb G5-conjugated Sepharose, resolved in an SDS–14% polyacrylamide gel, and visualized by autoradiography. Lane 1, 4 × 10^13 untreated viral particles; lane 2, 4 × 10^11 viral particles treated with trypsin; lane 3, supernatant from trypsin digest (shown in lane 2) after incubation with MAb G5-conjugated Sepharose; lane 4, trypsin-generated virion cleavage products (from a total of 2 × 10^13 viral particles) bound to MAb G5-conjugated sepharose. Viral proteins are labeled. Positions of molecular weight standards (in kilodaltons) are indicated. An arrow indicates the σ1 cleavage product (lane 4) isolated by using MAb G5-conjugated Sepharose. This band was used as a reference to identify the Coomassie blue-stained σ1 cleavage product (see Materials and Methods) subjected to amino-terminal sequence analysis. (B) Identification of the trypsin cleavage site in virion-associated T3D σ1 protein. Amino-terminal residues 1 through 8 of the trypsin-generated σ1 cleavage product are aligned with a region of sequence proposed to form the σ1 neck, amino acids 239 to 259 (47). Positions in boxes occur in the α or d position of a heptad repeat motif characteristic of α-helical coiled coils (42). This alignment indicates that trypsin cleaves σ1 between Arg245 and Ile246 during the generation of ISVPs. The cleavage site in σ1 primary sequence is indicated by an arrow.

FIG. 9. Analysis of viral structural proteins following generation of ISVPs by using a murine intestinal wash. Purified 35S-labeled virions of T1L, T3D, T3C9, T3C31, or T3C84 at a concentration of 3.3 × 10^11 particles per ml were treated with various concentrations of a murine intestinal wash (int. wash) at 20°C for 3.5 h. Aliquots of 12 μl were heated at 100°C in sample buffer and subjected to electrophoresis in an SDS–10% polyacrylamide gel, followed by autoradiography to visualize viral proteins. Viral proteins are labeled. The σ1 protein is indicated by an arrow. ▼, 0 to 83% (vol/vol) intestinal wash.
tion. Thr249 is not the site of protease action; rather, this residue mediates cleavage at a nearby site, Arg245. Algorithms to predict secondary structure suggest that the 1 protein is controlled indirectly by amino acid 249, perhaps through an effect on subunit interactions. Furthermore, these results establish a molecular model to explain viral infectivity loss in vitro (46) and in vivo (9, 32).

Identification of an amino acid residue in T3D 1 protein that determines susceptibility to cleavage by protease. The identification of a sequence polymorphism that correlates with 1 cleavage susceptibility was facilitated by the characterization of type 3 reovirus strains that vary in infectivity loss and cleavage of 1 following protease treatment of virions to generate ISVPs. By comparing deduced 1 amino acid sequences of these strains, we found that both infectivity loss and 1 cleavage exhibited by strains T3D and T3C31 are correlated with sequence polymorphism at a single amino acid position in 1, residue 249 (Fig. 5). This correlation strongly suggests that amino acid 249 is the sole determinant of type 3 1 cleavage by protease but does not exclude the potential contribution of other amino acid positions where sequence similarity (as opposed to sequence identity) is correlated with cleavage sensitivity. In concordance with the sequence correlation, expressed 1 protein substituted at Thr249 with an isoleucine was not cleaved by trypsin, despite nearly complete cleavage of wild-type protein (Fig. 6B). This result confirms that the amino acid residue at position 249 is an independent determinant of 1 cleavage by protease.

Though conferring resistance to cleavage by trypsin, the Thr249→Ile replacement did not prevent cleavage by chymotrypsin (Fig. 6A). This result was unexpected since field isolate reovirus strains containing an isoleucine residue at 1 amino acid position 249 have chymotrypsin-resistant 1 proteins. However, our results do not necessarily suggest different mechanisms of 1 cleavage sensitivity with respect to trypsin and chymotrypsin. It is possible that baculovirus-expressed type 3 1 protein adopts a conformation slightly different from that of virion-associated 1 and that this conformation confers sensitivity to chymotrypsin cleavage by a mechanism unrelated to sequence polymorphism at position 249. Alternatively, resistance of type 3 1 protein to cleavage by chymotrypsin may require association of 1 with other proteins of the reovirus virion, such as outer-capid protein 3 or core-spike protein 4, both of which likely interact with 1 (20, 29, 34, 38, 63).

Sites of 1 cleavage during protease treatment of T3D virions to generate ISVPs. We determined the site of 1 cleavage on T3D ISVPs to better understand properties of receptor-binding domains of type 3 1 protein. In studies of attachment by T3D ISVPs, we found that following 1 cleavage, sequences in 1 that bind sialic acid remain particle associated despite loss of a receptor-binding domain in the 1 head (46). This model is supported by results of amino-terminal sequence analysis of T3D 1 proteolytic cleavage products liberated during the generation of ISVPs (Fig. 8B). The cleavage site mapped by using trypsin is carboxyl terminal to sequences in the tail that determine sialic acid binding and amino terminal to sequences in the head that bind a receptor on L cells (41, 45, 67, 70). Results of the sequence determination are also consistent with the finding that HA titers of T3D and T3C31 ISVPs were not lower than those of intact virions (Fig. 4). In fact, 1 sequences that bind sialic acid appear to be more accessible to sialylated ligands on the erythrocyte surface since the HA titer increased when type 3 reovirus virions were converted to ISVPs by using chymotrypsin. Based on these results, we conclude that type 3 1 protein possesses a modular arrangement of receptor-binding domains and that binding of sialic acid is a function of the tail, perhaps directly involving sequences predicted to form a β-sheet motif.

Mechanism of type 3 1 protein susceptibility to cleavage by proteases. The amino terminal of the two proposed coiled-coil units in the 1 neck contains three classical heptad repeats in which apolar residues occupy the first and fourth amino acid positions (47). Residue 249 is located in the d position of the second heptad repeat (Fig. 5). Since trypsin and chymotrypsin preferentially cleave adjacent to basic and bulky aromatic residues, respectively (12), a threonine at position 249 in T3D 1 is not predicted to be the site of protease action. Concordantly, no cleavage at this site was indicated by amino-terminal sequence analysis of T3D 1 cleavage products (Fig. 8B). One plausible mechanism of cleavage sensitivity is that the presence of threonine disrupts hydrophobic contacts between apolar α-helices, which then allows protease to attack a neighboring target sequence. Conversely, the presence of an isoleucine is predicted to favor a more stable interhelical association and thereby shield the protease target site. This model is supported by the finding that protease resistance could be engineered by replacement of Thr249 with isoleucine as well as another hydrophobic amino acid, leucine, but not by replacement with a polar amino acid, asparagine (Fig. 6B). Additionally, a trypsin cleavage site (Arg245) in virion-associated T3D 1 protein was identified within four residues of Thr249, which is consistent with the prediction that interfacial contacts of an α-helical coiled coil would be locally destabilized by the occurrence of a
polar residue in the $d$ position of a heptad repeat. The $\sigma 1$ oligomer has been modeled as either a coiled-coil homotrimer (40, 58) or a pair of parallel coiled-coil homodimers (24). It is possible that a polar residue at position 249 makes protease cleavage sites accessible by causing a localized decrease in the compactness of either a dimeric or trimeric coiled coil or by indirectly perturbing the stable association between pairs of coiled-coil dimers.

Our experiments do not directly address putative conformational differences in the $\sigma 1$ neck in its cleavage-susceptible and cleavage-resistant states, and it is possible that the effect of Thr249 is to disrupt intramolecular $\sigma 1$ structure. Confirmation of the mechanism of $\sigma 1$ cleavage susceptibility will require further characterization of the neck region by using biophysical techniques.

Cleavage of $\sigma 1$ protein and reovirus pathogenesis. The cleavage status of type 3 $\sigma 1$ protein in vivo is unknown. Virions of T1L orally inoculated into newborn mice are rapidly converted to ISVPs in the intestinal lumen (10). Furthermore, proteolytic processing of virions to ISVPs is an obligate step in reovirus infectivity in the intestine (1, 6). A reasonable inference from these findings is that the $\sigma 1$ proteins of T3D and T3C31 are cleaved in the murine intestine. We tested this possibility by treating virions with the contents of a murine intestinal lavage under conditions that lead to the generation of ISVPs. Examination of viral structural proteins by SDS-PAGE showed that the $\sigma 1$ proteins of both strains were cleaved under these conditions; however, the $\sigma 1$ proteins of strains T3C9 and T3C84 remained intact (Fig. 9). This pattern of $\sigma 1$ cleavage sensitivity replicates results obtained for both virions and expressed $\sigma 1$ protein in in vitro cleavage assays with purified protease (Fig. 3, 6B, and 7). Therefore, these results indicate that $\sigma 1$ proteins of type 3 reovirus strains are differentially susceptible to cleavage during the course of natural infection.

T3D is avirulent when infection is initiated in the intestine (31, 54, 68), even though this virus is neurotropic (23, 61, 65) and highly neurovirulent (23, 31, 44, 57, 62) following intramuscular or intracranial inoculation. Therefore, cleavage of T3D $\sigma 1$ protein by intraluminal proteases, as shown here, may contribute to the avirulence of this strain in newborn mice inoculated orally. This model is supported by linkage of the S1 gene to differences in T1L and T3D growth and spread following peroral inoculation (9, 32). Verification of this hypothesis will require genetic analysis of the in vivo cleavage susceptibility of T3D $\sigma 1$. However, if $\sigma 1$ stability in the intestinal lumen is a virulence determinant of reovirus, it is not necessarily the predominant influence on virulence after oral inoculation; 50% lethal doses reported for type 3 strains (including T3D, T3C9, T3C31, and T3C84) (68) do not correlate with patterns of $\sigma 1$ cleavage susceptibility observed in this study. We are conducting studies on a variant of T3D adapted to growth in murine intestinal tissue (28) to better understand the precise relationship between $\sigma 1$ stability and reovirus pathogenesis.

Function of the $\sigma 1$ neck domain. The neck region likely exhibits considerable flexibility since this portion of the protein is highly sensitive to proteolysis (22; Fig. 8B) and shows enhanced curvature in analyses of $\sigma 1$ visualized by electron microscopy (14, 24, 25). Flexibility in the $\sigma 1$ neck may optimally orient sequences in the head and tail for receptor engagement and viral entry. This situation would be similar to attachment by bacteriophage T4, where the latent receptor-binding domain in the short tail fiber is repositioned to an active orientation by extension of the fiber at a proposed hinge (43). Another function of the $\sigma 1$ neck may be to promote intraenveloped virion disassembly by undergoing conformational adjustments that alter interactions between $\sigma 1$ and neighboring outer-capsid components, such as the $\sigma 3$ protein (34, 38, 63). Indeed, mutations in both $\sigma 1$ and $\sigma 3$ proteins confer the ability of virions to bypass blocks to disassembly within the endosome (66, 69), suggesting a cooperative interaction of $\sigma 1$ with $\sigma 3$ in the dissociation of outer-capsid proteins. Additional sites in the $\sigma 1$ tail, near the middle and near the virion-proximal amino terminus, also show evidence of flexibility (24), and concerted adjustments at these positions and the neck region may facilitate the dramatic conformational change in $\sigma 1$ observed when the outer capsid is degraded by protease to produce an ISVP (25). Functions of the $\sigma 1$ neck in reovirus infection will become clearer as the structure and conformational dynamics in this region of $\sigma 1$ are elucidated.

ACKNOWLEDGMENTS

We thank Mehmet Goral, Patrick Green, and Gerald Stubbs for critical review of the manuscript. We also thank Joy Duong of the Elizabeth B. Lamb Center for Pediatric Research and Eric Howard and Masaaki Tamura of the Protein Chemistry Laboratory, Department of Biochemistry, Vanderbilt University School of Medicine, for expert technical assistance.

This research was supported by PHS awards AI39533 (M.L.N.) and AI38296 (J.D.C. and T.S.D.) from the National Institute of Allergy and Infectious Diseases, PHS award T32 GM07347 from the National Institute of General Medical Sciences for the Vanderbilt Medical-Scientist Training Program (G.S.B. and D.T.D.), and Vanderbilt Diabetes Research and Training Center grant P60 DK20593. This work also was supported by the National Science Foundation and University Research Council, Vanderbilt University (E.S.B.), an Amos Christie fellowship from the Department of Pediatrics at Vanderbilt University School of Medicine (T.H.S.), and the Elizabeth B. Lamb Center for Pediatric Research.

REFERENCES

16. Chappell, J. D., V. L. Gunn, J. D. Wetzel, G. S. Baer, and T. S. Dermdy. 1997. Mutations in type 3 reovirus that determine binding to sialic acid are
43. Makov, A. M., B. L. Trus, J. F. Conway, M. N. Simon, T. G. Zurabishvili, V. V. Meyts-van Limbeck, and A. C. Steven. 1993. The short tail-fiber of bacte-